Outcomes Measurement Leader launches QOLIX®, First-of-Its-Kind Quality of Life Measurement System

Emirates PharmaAdvertisement

John Ware Research Group, Inc.,(JWRG), a leading health outcomes company, announces the launch of QOLIX, a patent pending Quality of Life Measurement Information System, a new, web-based patient-centered measurement application which improves patient outcomes measurement and makes them more usable in patient-centered care, outcomes monitoring, clinical trials, patient registries, predictive outcomes, and population health studies.

QOLIX is the field’s first patient reported outcomes (PRO) system to offer integrated generic and disease-specific assessments developed and evaluated together to provide more information about a patient’s condition resulting in improved interpretation.

“We are pleased to be advancing the PRO field with the introduction of QOLIX. It offers ‘one-stop shopping’ for the Researcher/Clinician who needs a brief but accurate patient assessment, real-time norm-based scoring, and clinical reports to provide support for clinical decision making, comparative effectiveness research, and evidence for clinical trials,” said John E. Ware, Jr., PhD, JWRG’s Founder and Chief Science Officer and globally recognized inventor of the PRO field.

On average, a 50% reduction in respondent burden is achieved in comparison to static forms still used today by applying a new Adaptive Survey Logic™, (ASLX®) process and CAT, a proven adaptive testing methodology which tailors questions administered based upon a respondent’s answer.

QOLIX is a feature rich, always-on SaaS application designed in response to clinician and researcher feedback coupled with breakthroughs in outcomes measurement science and current technology. Its dashboard allows sponsors control from pre-study design customization through real-time data exports. QOLIX’s API allows integration with EHRs, other clinical records, clinical trials, or other PRO systems.

“Offering more choices to sponsors significantly reduces research costs. With QOLIX’s library of 35 conditions, sponsors have alternatives to developing costly disease-specific PRO’s or hiring third-party vendors to program paper surveys. They can access a scientifically-valid system offering great flexibility, thanks to technological advances in the application,” said Rosemarie Boulanger, JWRG’s President.

PRO’s are used in clinical trials for seeking FDA approval for label claims for certain drugs or medical devices regarding quality of life improvements. Clinicians use PRO’s as clinical support tools for a variety of conditions.

The QOLIX system is available only for scholarly research studies in the U.S and available for all purposes elsewhere.

 

 

 

Emirates PharmaAdvertisement